For in vitro diagnostic use. Others Elecsys proBNP II IVD Elecsys® proBNP II CPS_000499 09 315 284 190 9 315 284 190 09315284190 9315284190 09315284190 proBNP G2 Elecsys E2G 300 V2.1 Elecsys proBNP II 07613336191521 Reagents, kits 300 tests cobas e 402/801 true 09 744 959 190 9 744 959 190 09744959190 9744959190 09744959190 proBNP G2 Elecsys E2G 100 V2.1 Elecsys proBNP II 07613336217689 Reagents, kits 100 tests cobas e 402/801 true 09 315 268 190 9 315 268 190 09315268190 9315268190 09315268190 proBNP G2 Elecsys cobas e 100 V2.1 Elecsys proBNP II 07613336191507 Reagents, kits 100 tests cobas e 411/601/602 true 09315284500 Elecsys proBNP II en 4 FF00000006309B0E FF0000000477020E 09315284190 09315284214 9494 cobas e 402 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Immunoassay for the in vitro quantitative determination of N‑terminal pro B‑type natriuretic peptide in human serum and plasma. This assay is indicated as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.The test also aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure. This assay is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.The test can help in the cardiovascular risk assessment of patients with type 2 diabetes mellitus. The test is further indicated to aid in the identification of patients at risk with type 2 diabetes mellitus, without known history of cardiovascular disease, to optimize cardioprotective treatment.This test can be used to identify elderly individuals at high-risk for atrial fibrillation.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09744959500 Elecsys proBNP II en 2 FF00000006B99A0E FF000000066F010E 09744959190 9494 cobas e 402 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Immunoassay for the in vitro quantitative determination of N‑terminal pro B‑type natriuretic peptide in human serum and plasma. This assay is indicated as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.The test also aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure. This assay is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.The test can help in the cardiovascular risk assessment of patients with type 2 diabetes mellitus. The test is further indicated to aid in the identification of patients at risk with type 2 diabetes mellitus, without known history of cardiovascular disease, to optimize cardioprotective treatment.This test can be used to identify elderly individuals at high-risk for atrial fibrillation.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09315268500 Elecsys proBNP II en 3 FF00000006304D0E FF0000000477000E 09315268190 2325 cobas e 602 619 cobas e 601 618 cobas e 411 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Immunoassay for the in vitro quantitative determination of N‑terminal pro B‑type natriuretic peptide in human serum and plasma. This assay is indicated as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.The test also aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure. This assay is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.The test can help in the cardiovascular risk assessment of patients with type 2 diabetes mellitus. The test is further indicated to aid in the identification of patients at risk with type 2 diabetes mellitus, without known history of cardiovascular disease, to optimize cardioprotective treatment.This test can be used to identify elderly individuals at high-risk for atrial fibrillation.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User profile

Select your user profile

Elecsys^® proBNP II

Overview

Ordering information

Technical documents

Compatible products

Contact us